Case report

Merkel cell carcinoma metastasis and dermatofibrosarcoma protuberans presenting as a collision tumour: a case report and review of the literature

Daniel-Johannes Tilkorn1*, Marcus Lehnhardt1, Jörg Hauser1, Adrien Daigler1, Heinz Homann1, Hans Steinau1 and Cornelius Kuhnen2

Addresses: 1Department of Plastic Surgery, Burn Center, Hand Center, Sarcoma Reference Center, BG-University-Hospital “Bergmannsheil”, Ruhr-University Bochum, Buerkle-de-la Camp Platz, 44789 Bochum, Germany and 2Institute of Pathology, BG-University-Hospital “Bergmannsheil”, Ruhr-University Bochum, Buerkle-de-la Camp Platz, 44789 Bochum, Germany

Email: DJT* - d.tilkorn@web.de; ML - marcus.lehnhardt@ruhr-uni-bochum.de; JH - joerg.hauser@ruhr-uni-bochum.de; AD - adrien.daigeler@rub.de; HH - heinz.homann@ruhr-uni-bochum.de; HS - hans-ulrich.steinau@bergmannsheil.de; CK - kuhnen@patho-muenster.de

* Corresponding author

Received: 7 August 2008   Accepted: 29 January 2009   Published: 30 June 2009

Journal of Medical Case Reports 2009, 3:7493 doi: 10.4076/1752-1947-3-7493

This article is available from: http://jmedicalcasereports.com/jmedicalcasereports/article/view/7493

© 2009 Tilkorn et al; licensee Cases Network Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Introduction: Merkel cell carcinoma and dermatofibrosarcoma protuberans are two very rare neoplasms. The simultaneous occurrence of two different tumour entities at the same anatomical site, collision tumours, is a rare phenomenon.

Case presentation: We present a rare case of a 74-year-old woman with a previous history of a recurrent dermatofibrosarcoma protuberans presenting with a metastatic Merkel cell carcinoma. Further investigation revealed a collision tumour of a metastatic lesion of the Merkel cell carcinoma within a tumour relapse of a dermatofibrosarcoma protuberans.

Conclusion: Synchronous occurrence of two different tumour entities is extremely rare and has not been described for Merkel cell carcinoma and dermatofibrosarcoma. Merkel cell carcinoma, a tumour of the elderly or immunocompromised patients, leads to early metastasis and can be expected to be the limiting factor for prognoses.

Introduction

Primary neuroendocrine tumour of the skin, also known as Merkel cell carcinoma (MCC), was first described by Toker in 1972. It is a rare but aggressive tumour entity of sun-exposed skin of the elderly in the age range of 60 to 90 years. The origin of this tumour is thought to be a line of differentiation according to Merkel cells. Under homeostatic conditions, the Merkel cells, discovered by Friedrich Merkel in 1875, are normal constituents of the basal layer of the epidermis and hair follicles. A higher density of Merkel cells is found in the glabrous epithelium of the digits, lips and oral cavity and hair bearing skin. They represent slow acting mechano-receptors with close contact to unmyelinated nervous fibres in the superficial
dermis. Whether these cells are of a neuroendocrine or epidermal-ectodermal nature is still unclear.

MCC, with a female predominance, [1] has a predilection for the head and neck region, a potential for early metastasis and is rarely encountered on the extremities and trunk. Conditions leading to impaired immunity, such as immunosuppression therapy [2], human immunodeficiency virus infection and chronic lymphocytic leukaemia have been associated with a higher incidence of MCC.

Dermatofibrosarcoma protuberans (DFSP) is another uncommon skin malignancy. As an intermediate neoplasm it has a local aggressive growth pattern but it rarely metastasizes. In the uncommon event of metastasis they are often found in the lungs and in the lymph nodes [3]. A high recurrence rate complicates the course of the disease and requires wide local excision with clear margins.

Clinically, DFSP often presents as slow growing nodular masses of the skin on the trunk or proximal extremities.

Simultaneous occurrence of two different tumour entities at the same anatomical site is a very rare event. Cases of haematopoietic neoplasms in association with breast and skin malignancies have been reported. To our knowledge this is the first reported case of a synchronous occurrence (collision tumour) of MCC and DFSP.

**Case presentation**

A 74-year-old, Caucasian woman from Germany with a long history of local recurrences of DFSP on her right upper limb was readmitted for surgical intervention of a tumour of her right axilla. On clinical examination she presented with two firm tumour masses in the right axilla and on the thoracic wall with a size of 6 × 7 cm and 6 × 5 cm. Both lesions displayed central ulceration. In addition, the patient requested the resection of a small (1.7 × 1.6 cm) nodular skin lesion of her right elbow region.

The DFSP of her right shoulder region was first diagnosed in 1991. Following several incomplete tumour resections and local progressive tumour growth she was transferred to our hospital in 2001. Tumour resection was carried out and radiation therapy was suggested but refused by the patient. Despite clear resection margins the tumour recurred locally 10 months later and, at this stage, the tumour had infiltrated the brachial plexus. Since then, additional surgical interventions for local recurrences of the DFSP were required every 5 to 9 months. Fifteen years after the initial diagnosis of the DFSP, at readmission for a local recurrence, the tumour extended from the axilla along the thoracic wall to the lateral aspect of the ipsilateral scapular and an additional small (less than 2 cm) reddish blue subcutaneous nodular lesion was observed at the dorsal aspect of the right elbow.

Histologically the two tumour masses in the axilla and thoracic wall confirmed the clinical diagnosis of a local recurrence of the known DFSP. The tumours were highly cellular with partly ovoid, partly spindle shaped nuclei with small fascicular cell formations. Due to these clear detectable fascicular areas, these recurrences were classified as DFSP with fibrosarcomatous transformation (Figure 1).

In contrast, the tumour from the elbow microscopically presented as a highly cellular small cell tumour lacking fascicular formations (Figure 2). Additional immunohistochemical analysis revealed punctual reaction of the vast majority of tumour cells for keratin MNF 116 with a cytoplasmatic distribution and a punctual perinuclear immune reaction for cytokeratin-20. The tumour was CD3, CD20 and LCA negative. A high proliferative activity index (Ki 67) of 70% was evident. The histological and immunohistochemical analysis verified the diagnosis of a Merkel cell carcinoma (pT1 pN0, pM0 R0).

The Merkel cell carcinoma was resected in total whereas a complete resection of the DFSP (pT2b, pN0, pM0, R2) with preservation of the extremity could not be achieved.

Six months after the surgery the patient suffered a synchronous local recurrence of both the DFSP and MCC (Figure 3). At this time the tumour specimen from the elbow histologically resembled the previously described MCC. The axillary specimen revealed an
infiltration of a spindle cell-like tumour with a partial storiform, partial fascicular, growth pattern. Within this tumour, an area of up to 1.1 cm with a small cell tumour infiltrate, correlating with the described Merkel cell tumour mixed with a spindle cell tumour formation, was found. The histological findings displayed a collision tumour of a metastasis of the Merkel cell tumour (pT3, pN0, pM1) and the relapse tumour of DFSP (pT2b, pN0, pM0, R2) (Figure 4). Further clinical and radiological tumour staging demonstrated no further evidence of metastatic disease.

For local tumour control, the option of an interthoracocapular amputation was discussed but not accepted by the patient. Therefore, palliative radiotherapy and chemotherapy with the tyrosine kinase inhibitor Imatinib was initiated.

Discussion
Both DFSP and MCC are very rare malignancies. Even though the occurrence of multiple malignancies in the same anatomical site in organs such as the thyroid, breast and lymph nodes [4] have been described previously, the occurrence of synchronous colliding tumours remains an extremely uncommon condition with a very limited number of cases in the literature. Single cases of the simultaneous appearance of MCC with chronic lymphatic leukaemia [5] or rhabdomyosarcoma [6] have been described. To our knowledge this is the first reported case involving MCC and DFSP; in this patient, a haematogenous metastasis of a MCC within a relapse tumour of DFSP located in the axilla.

Even though the association between these two tumours in our patient is most likely coincidental, immunosuppression during a long course of previous tumour disease of the right upper extremity might be accountable for an increased risk of developing a secondary malignancy such as the MCC.

Clinical studies and animal experiments demonstrate the fact that malignant tumours lead to an altered immune status systemically, as well as locally, through changes in the microenvironment. Functional impairment of T-lymphocytes in addition to an accumulation of chronically activated myeloid suppressor cells and regulatory T-cells has been observed systemically. This may lead to a disabled tumour killing CD 8 CTL response and enhance cancer development through activation of other immune cells.
Changes in local microenvironment, for example an increase in certain pro-inflammatory cytokines and pro-angiogenic mediators such as interleukin 1 and 6 (IL1, IL6) tumour necrosis factor (TNFα) and vascular endothelial growth factor (VEGF), is one mechanism by which the tumour infiltrating leucocytes promote tumour growth, cell survival and an increase in tumour angiogenesis [7,8].

Many studies have confirmed an increase in certain matrix metalloproteinases (MMPs) altering tissue homeostasis through various biological pathways such as remodelling of the extracellular matrices, increase in cell-cell and cell-matrix adhesion molecules and thereby altering intracellular signalling pathways and often correlating with a poorer prognosis. But many of the mechanisms involved in tumour immunology and tumorigenesis, differentiation and dedifferentiation of cancer stem cells are still unknown, especially mechanisms involved in the synchronous appearance of malignant tumours [9].

For both malignancies described here, surgical resection of the tumour with clear surgical margins is the main choice of treatment. Both tumours are very rare neoplasms with a similar incidence of four cases or less per million per year. DFSP may affect patients of all ages but is rarely encountered during childhood and it mainly occurs in adults between 20 and 40 years of age. It is a tumour of the dermis and subcutis characterized by a local aggressive growth pattern. Its asymmetric growth and pseudopod-like extensions aggravate tumour resection and account for a high rate of local recurrence of up 60% [10]. A strong correlation between surgical margins and tumour free survival has been demonstrated. Invasion of the underlying fascia and muscle has been observed in patients with a long history of DFSP. In these cases wide local resection may be mutilating and in this case an interthoracoscopic resection would have been required. Fibrosarcomatous transformation of DFSP results in an increased risk of distant metastasis especially into the lungs and an even higher rate of local recurrence [11,12].

Radiotherapy has been successful in gaining local tumour control. DFSP has been found to be non-chemotherapy sensitive. Recently the tyrosine kinase inhibitor Imatinib has demonstrated an antitumorigenic effect with promising results for patients with metastatic disease as well as for local tumour control [13]. MCC on the other hand is a cutaneous small cell carcinoma of the elderly with a female predominance [1]. Impaired immune status due to viral infections or immunosuppression therapy has been linked to an increased risk of developing MCC [5]. In the case described here the patient had no history of immunosuppressive therapy and displayed no reasonable grounds to suspect HIV infection even though this was not confirmed by laboratory testing.

In the last 7 years, 12 patients with a MCC were treated in our clinic. Interestingly, four of these 12 patients had a history of an underlying previous malignancy and one additional patient suffered from chronic renal failure. Both conditions possibly lead to a compromised immune response. Compared to other extra pulmonary small cell cancers MCC appears to have a favourable prognosis but it remains an aggressive tumour with a frequent recurrence, early metastases and high mortality rates. In contrast to melanoma, which also represents a neuroendocrine tumour of the skin, tumour thickness seemingly is of no prognostic value. Regional lymph node status appears to influence local recurrence but not the overall prognosis [14]. MCC has the potential for haematogenous metastasis mainly affecting the lungs as well as lymphatic metastasis. Distant metastasis is the limiting prognostic factor. Similar to other small cell carcinomas radiotherapy and chemotherapy sensitivity has been described. Various clinical and histological parameters have been evaluated regarding their predictive prognostic value but findings remain contradictory [15].

**Conclusions**

Both MCC and DFSP are uncommon tumour entities of elderly or immunocompromised patients. Collision tumours are extremely rare and have never been described for MCC and DFSP. In this patient the distant metastasis of the MCC is expected to be the limiting factor for survival.
Abbreviations
MCC, Merkel cell carcinoma; DFSP, dermatofibrosarcoma protuberans; MMPs, matrix metalloproteinases; VEGF, vascular endothelial growth factor.

Consent
Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
DT conceptualised the case report, gathered the data and wrote the manuscript. ML drafted and revised the manuscript and was involved in the primary surgery. JH gathered the clinical data and assisted with postoperative care of the patient. AD reviewed the literature and assisted in the follow up treatment of the patient. HH performed the primary surgery and took responsibility for the patient’s care. HS conceptualised and supervised the process and he gave final approval for publication. CK assessed the histological specimens and drafted and revised the manuscript. All authors read and approved the final manuscript.

Acknowledgement
We thank Mr Sammy Al Benna for his help with the language revision of the manuscript.

References
1. Hundeiker MAU, Lippold A: Merkelzell-Karzinome der Haut. Bericht ueber 102 untersuchte Patienten. Fortschritte der Opativen und onkologischen Dermatologie 2003, 19:55-59.
2. Pein I, First MR: Merkel's cell carcinoma in organ recipients: report of 41 cases. Transplantation 1999, 68:1717-1721.
3. Ding J, Hashimoto H, Enjoji M: Dermatofibrosarcoma protuberans versus fibrosarcomatous areas. A clinicopathologic study of nine cases and a comparison with allied tumors. Cancer 1989, 64:721-729.
4. Pandey U, Naraynan M, Karnik U, Sinha B: Carcinoma metastasis to unexpected synchronous lymphoproliferative disorder: report of three cases and review of literature. J Clin Pathol 2003, 56:970-971.
5. Barroeta JE, Farkas T: Merkel cell carcinoma and chronic lymphocytic leukemia (collision tumor) of the arm: a diagnosis by fine-needle aspiration biopsy. Diagn Cytopathol 2007, 35:293-295.
6. Fernandez-Figueras MT, Puig L, Gilberte M, Gomez-Plaza Mdel C, Rex J, Ferrandiz C, Ariza A: Merkel cell (primary neuroendocrine) carcinoma of the skin with nodal metastasis showing rhabdomyosarcomatous differentiation. J Cutan Pathol 2002, 29:619-622.
7. Balkwill F, Charles KA, Mantovani A: Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 2005, 7:211-217.
8. Tan TT, Coussens LM: Humoral immunity, inflammation and cancer. Curr Opin Immunol 2007, 19:209-216.
9. de Visser KE, Echten A, Coussens LM: Paradoxical roles of the immune system during cancer development. Nat Rev Cancer 2006, 6:24-37.
10. Gloster HM Jr: Dermatofibrosarcoma protuberans. J Am Acad Dermatol 1996, 35:355-374.
11. Mentzel T, Beham A, Katenkamp D, Dei Tos AP, Fletcher CD: Fibrosarcomatous (“high-grade”) dermatofibrosarcoma protuberans: clinicopathologic and immunohistochemical study of a series of 41 cases with emphasis on prognostic significance. Am J Surg Pathol 1998, 22:576-587.
12. Snow SN, Gordon EM, Larson PO, Bagheri MM, Bentz ML, Sable DB: Dermatofibrosarcoma protuberans: a report on 29 patients treated by Mohs micrographic surgery with long-term follow-up and review of the literature. Cancer 2004, 101:28-38.
13. Sjoblom T, Shimizu A, O’Brien KP, Pieras K, Dal Cin P, Buchdunger E, Dumanski JP, Ostman A, Heldin CH: Growth inhibition of dermatofibrosarcoma protuberans tumors by the platelet-derived growth factor receptor antagonist STI571 through induction of apoptosis. Cancer Res 2001, 61:5778-5783.
14. Goldberg SR, Neefeld JP, Frable WJ: Prognostic value of tumor thickness in patients with Merkel cell carcinoma. J Surg Oncol 2007, 95:618-622.
15. Skelton HG, Smith KJ, Hitchcock CL, McCarthy WF, Lupton GP, Graham JH: Merkel cell carcinoma: analysis of clinical, histologic, and immunohistologic features of 132 cases with relation to survival. J Am Acad Dermatol 1997, 37:734-739.

Do you have a case to share?
Submit your case report today
• Rapid peer review
• Fast publication
• PubMed indexing
• Inclusion in Cases Database

Any patient, any case, can teach us something

www.casesnetwork.com